Mounjaro joins China's National Reimbursement Drug List

Eli Lilly's tirzepatide, sold as Mounjaro, was added to China's National Reimbursement Drug List (NRDL) effective January 1, 2026 ^[1]. By the second quarter, the effect showed up clearly in Lilly's books: much lower prices per unit, and far more units sold.

Lilly reported that revenue outside the United States jumped 80% to $8.6 billion in the second quarter of 2026, driven by a 113% surge in volume and partly offset by a 36% drop in realized prices ^[2]. The company attributed the bulk of that price decline to Mounjaro's addition to China's state-run health insurance coverage for type 2 diabetes ^[2]. China revenue grew 93% at constant currency, driven by Mounjaro uptake ^[3].

A price-for-volume trade

NRDL listing in China typically means a government-negotiated price in exchange for national coverage. In Lilly's case, the trade appears to have worked in revenue terms: Mounjaro's worldwide sales rose 91% to $9.94 billion in the quarter, including $4.8 billion in the U.S., beating analyst expectations of $8.99 billion worldwide ^[2]. Sales outside the U.S. jumped 172% ^[2].

It is worth being precise about what China's listing covers. According to Lilly's reported figures, the reimbursement applies to type 2 diabetes ^[2]. Coverage for obesity is a separate question that the sources do not address, so the status of reimbursed obesity use in China is not yet known from this reporting.

Much of the demand in large middle-income markets is still paid for by patients directly. CEO Dave Ricks said most people are paying out of pocket for Mounjaro in countries such as Brazil, China and India, where Lilly is "seeing very strong and durable demand" ^[2].

Competition is also a factor. Morgan Stanley noted that generic semaglutide in China appears delayed into 2026 for the type 2 diabetes indication, with obesity potentially following even later, based on disclosures from Jiuyuan Gene and Livzon Pharma Group ^[1]. In India, where generic semaglutide already launched, Mounjaro still grew roughly 10%, which the bank described as a "halo effect" from broader category awareness ^[1]. Lilly said tirzepatide prescription growth continued in India and Brazil even after generic semaglutide launched ^[3].

The broader numbers

Lilly's total second-quarter revenue was $22.97 billion, up 48% year over year, against analyst expectations of $20.73 billion ^[2][3]. The company raised full-year 2026 revenue guidance to $85 billion to $87 billion from $82 billion to $85 billion ^[2]. Zepbound, the tirzepatide product approved for weight management, posted $4.93 billion in revenue, up 46% ^[2]. Foundayo (orforglipron), Lilly's oral GLP-1 approved in the U.S. in April, recorded $98 million in its first reported quarter, slightly below the roughly $103 million analysts expected ^[2].

In the U.S., the price direction is downward too, though less dramatically. Lilly said U.S. revenue climbed 33% to $14.4 billion on a 37% increase in volume, partly offset by lower realized prices ^[2]. U.S. price declined 3%, or 9% excluding rebate and discount estimate adjustments ^[3]. Roughly 45% of Zepbound prescriptions in the quarter were self-pay, and about 55% of new prescriptions ^[3].

Why it matters for patients

China's listing is a large-scale example of what happens when a government negotiates a GLP-1 price down: the per-patient price falls sharply and the number of patients rises steeply. The 36% drop in realized international prices against a 113% volume increase is the clearest published illustration so far of that trade-off ^[2].

For U.S. patients, the direct effect is indirect. None of these China prices apply in the United States, and the sources do not suggest they will. But the pattern matters for two reasons. First, it supports Ricks's stated expectation, made in a late-April interview, that lower prices accelerate prescription volumes; he estimated global GLP-1 use would rise from about 20 million patients at the end of last year to 30 million by the end of 2026 ^[2]. Second, strong international volume gives Lilly revenue that is not dependent on U.S. list prices.

In the U.S., the bigger near-term access change is Medicare's new obesity drug coverage, which launched July 1 and lets eligible seniors get branded GLP-1s for a $50 monthly copay ^[2]. Lilly described the program as covering 20 million eligible Americans ^[3]. Ricks said the rollout is "off to a strong start" ^[2].

What happens next

Morgan Stanley expects China to be a meaningful volume driver in the second half of 2026, as reimbursement expands while generic competition stays delayed ^[1]. Lilly also said Mounjaro is now reimbursed for both type 2 diabetes and obesity in France ^[3]. Foundayo is under regulatory review in more than 40 additional countries, with a global rollout expected in all major markets in 2027 ^[3].